Workflow
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - Coherus Oncology reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, marking an earnings surprise of -9.68% [1] - The company posted revenues of $10.25 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.32%, but this represents a significant decline from year-ago revenues of $64.98 million [2] - Over the last four quarters, Coherus has surpassed consensus EPS estimates only once, indicating inconsistent performance [2] Stock Performance - Coherus Oncology shares have declined approximately 33.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for Coherus is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $12.78 million, and for the current fiscal year, it is -$1.21 on revenues of $58.33 million [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is currently in the top 41% of Zacks industries, which may positively influence stock performance [8]